RCT of HeartBot in Women

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT07416734
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Participants Must be Women Aged 25 Years or Older
  • Participants Should Have no Self-reported History of Heart Disease or Stroke
  • Participants Should Have no Terminal Illness or Diagnosed Cognitive Impairment, Including Alzheimer's Disease
  • Participants Should Not be Employed in the Healthcare Field
  • Participants Should Not be a Healthcare Professionals or Healthcare Trainees
  • Participants Should Possess a Smartphone With an Active Data Plan or Access to Wi-Fi
  • Participants Should Reside in the United States and be a University of California, San Francisco Health Patient

Eligibility Criteria

Sex
FEMALE
Age
25 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • HeartBot II Program — OTHER
    Participants assigned to the intervention group will receive the HeartBot II intervention during the first 12 weeks. Participants in the intervention group will download the HeartBot II application on their smartphone, register their account with the access code provided by the research team, and will be asked to start Module 1 immediately after randomization. The HeartBot II application consists of 4 module and each module is scheduled approximately 3 weeks apart. It will take about 13 minutes to complete each modules.
  • Waitlist Control — OTHER
    The waitlist control group will not receive the HeartBot II intervention during the initial 12-week period, but will receive a text message once week for 12 weeks for attention control. These text messages do not include any educational content related to heart attack or heart health and are limited to neutral study reminders and general self-report prompts. Following completion survey at week 12, participants in the waitlist control group will initiate the HeartBot II program, delivered identically to the intervention group.

Study Details

The goal of this clinical trial is to find out whether an app-based program called HeartBot II, which uses an artificial intelligence (AI) chatbot, can help improve women's awareness and knowledge of heart attacks in women. This is an online study with about 200 women taking part. Participants will be randomly assigned (by chance) to one of two groups: an intervention group or a wait-list control group. Participants in the intervention group will begin using the HeartBot II program right away. Participants in the wait-list control group will wait 12 weeks before starting the HeartBot II program. The HeartBot II program includes four short modules. In each module, participants will interact with a chatbot and spend about 10 to 15 minutes completing the content. Participants will be asked to complete an online screening and baseline survey at the start of the study, as well as two follow-up surveys at 12 weeks and 24 weeks.

Key Dates

Start date
Mar 1, 2026
Status verified
Feb 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: HeartBot Intervention
  • Active Comparator: Waitlist Control

Primary Outcome Measure

Awareness and knowledge of symptoms and response to a heart attack [ Time Frame: Baseline, week 12, week 24 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143
Yoshimi Fukuoka, Ph.D., RN, FAAN
[email protected]
415-476-8419

Find similar trials in San Francisco, CA

By research site
University of California, San Francisco· San Francisco, CA